Person: Thomas Bucknum

A COMPREHENSIVE SERIES OF ARTICLES ON THIS TOPIC

Biogen confirms securities law probe

BIOGEN IDEC INC yesterday said US securities regulators are formally probing whether there were any violations of securities laws related to suspension of its multiple sclerosis drug Tysabri.

Sat, 30 Apr, 2005

Elan chief waives his annual bonus

THE chief executive of Elan waived his annual bonus, worth about $900,000, last year, it emerged yesterday.

Tue, 12 Apr, 2005

ISEQ down as Elan rallies

The ISEQ index was down 15.31 points mid-morning at 6141.19.

Thu, 10 Mar, 2005

Biogen accused of insider dealing

A class action lawsuit has been taken in the United States against directors of Biogen Idec alleging insider dealing in the shares.

Fri, 04 Mar, 2005